Table 1.
Association of plasma sPD-L1 and STAT3 levels with the clinical characteristics of patients with DLBCL
| Clinical Parameters | n | sPD-L1 level | STAT3 level | ||||||
|---|---|---|---|---|---|---|---|---|---|
| High (%) | Low (%) | χ2 | P value | High (%) | Low (%) | χ2 | P value | ||
| Total | 87 | 44 (50.6) | 43 (49.4) | 44 (50.6) | 43 (49.4) | ||||
| Gender | |||||||||
| Male | 41 | 20 (48.8) | 21 (51.2) | 0.1 | 0.752 | 19 (46.3) | 22 (53.7) | 0.556 | 0.456 |
| Female | 46 | 24 (52.2) | 22 (47.8) | 25 (54.3) | 21 (45.7) | ||||
| Age (years) | |||||||||
| ≤ 60 | 59 | 30 (50.8) | 29 (49.2) | 0.005 | 0.941 | 29 (49.2) | 30 (50.8) | 0.148 | 0.700 |
| > 60 | 28 | 14 (50) | 14 (50) | 15 (53.6) | 13 (46.4) | ||||
| Subtype | |||||||||
| GCB | 39 | 15 (38.5) | 24 (61.5) | 4.149 | 0.042* | 22 (56.4) | 17 (43.6) | 0.963 | 0.326 |
| Non-GCB | 48 | 29 (60.4) | 19 (39.6) | 22 (45.8) | 26 (54.2) | ||||
| Clinical stage | |||||||||
| I-II | 45 | 17 (37.8) | 28 (62.2) | 6.107 | 0.013* | 18 (40) | 27 (60) | 4.170 | 0.041* |
| III-IV | 42 | 27 (64.3) | 15 (35.7) | 26 (61.9) | 16 (38.1) | ||||
| IPI grades | |||||||||
| 0-2 | 60 | 24 (40) | 36 (60) | 8.649 | 0.003* | 26 (43.3) | 34 (56.7) | 4.056 | 0.044* |
| 3-5 | 27 | 20 (74.1) | 7 (25.9) | 18 (66.7) | 9 (33.3) | ||||
| LDH level | |||||||||
| Normal | 49 | 19 (38.8) | 30 (61.2) | 6.248 | 0.012* | 22 (44.9) | 27 (55.1) | 1.446 | 0.229 |
| Elevated | 38 | 25 (65.8) | 13 (34.2) | 22 (57.9) | 16 (42.1) | ||||
| β2-M level | |||||||||
| Normal | 70 | 29 (41.4) | 41 (58.6) | 11.988 | 0.001* | 32 (45.7) | 38 (54.3) | 3.386 | 0.066 |
| Elevated | 17 | 15 (88.2) | 2 (11.8) | 12 (70.6) | 5 (29.4) | ||||
| Symptom | |||||||||
| A | 72 | 32 (44.4) | 40 (55.6) | 6.278 | 0.012* | 35 (48.6) | 37 (51.4) | 0.644 | 0.422 |
| B | 15 | 12 (80) | 3 (20) | 9 (60) | 6 (40) | ||||
| Extra nodal involvement | |||||||||
| No | 31 | 12 (38.7) | 19 (61.3) | 2.712 | 0.1 | 17 (54.8) | 14 (45.2) | 0.350 | 0.554 |
| Yes | 56 | 32 (57.1) | 24 (42.9) | 27 (48.2) | 29 (51.8) | ||||
| Double-expressor lymphoma | |||||||||
| Yes | 28 | 18 (64.3) | 10 (35.7) | 7.701 | 0.021* | 15 (53.6) | 13 (46.3) | 0.293 | 0.864 |
| No | 32 | 10 (31.3) | 22 (68.7) | 15 (46.9) | 17 (53.1) | ||||
| NA | 27 | 16 (59.3) | 11 (40.7) | 14 (51.9) | 13 (48.1) | ||||
| Clinical response | |||||||||
| CR/PR | 50 | 18 (36) | 32 (64) | 9.991 | 0.002* | 23 (46) | 27 (54) | 0.984 | 0.321 |
| SD/PD | 37 | 26 (70.3) | 11 (29.7) | 21 (56.8) | 16 (43.2) | ||||
sPD-L1; soluble programmed cell death ligand 1; STAT3, signal transducer and activator of transcription 3; DLBCL, diffuse large B cell lymphoma; GCB, germinal center B-cell; IPI, international prognostic index; LDH, lactate dehydrogenase; β2-M, beta 2 microglobulin, CR/PR, complete response/partial response; SD/PD, stable disease/progressed disease. *P < 0.05.